The project “Research and production of biochips based on DNA microarray technology for the diagnosis of some human diseases”, belongs to the Program to develop a number of high-tech industries managed by the Ministry of Industry and Trade. The goal of the project is to master the technology of manufacturing biochips based on DNA microarray; to produce biological chip sets that meet the quality standards of in vitro diagnostic biological products – IVD; At the same time, these biochips can be applied to clinical diagnosis. BIMEDTECH officials and employees implement the project To implement the project, BIMEDTECH collaborated with leading units such as the National Institute of Hematology and Blood Transfusion, the Central Lung Hospital and the Cardiology Institute – Bach Mai Hospital to conduct surveys of known gene mutations. found in biochips of international production and a number of new or specific genetic mutations in humans and pathogens in Vietnam that are associated with diseases: thalassemia, 17 bacterial strains non-tuberculosis (NTM) and clopidogrel-resistant patients in patients undergoing cardiovascular intervention. Along with that, BIMEDTECH has invested in building a clean room system and the world’s leading advanced and modern equipment and machines into the factory in the Hi-Tech Park of Ho Chi Minh City. BIMEDTECH has signed cooperation agreements with high-tech companies in the United States and Europe to receive technology transfer for the production of DNA and Protein Microarray, the foundation for developing products for the diagnosis of a number of diseases in Vietnam. people. Take the lead in mastering technology With the support of the program, BIMEDTECH team has developed 3 products: BIMEDCHIP Thalassemia Detection Kit for diagnosis and treatment of thalassemia. This is the first in vitro diagnostic kit product made in Vietnam that allows simultaneous detection of many mutations causing congenital anemia including alpha and beta – thalassemia in just one test with accurate results. , fast time to get results with suitable cost. Thalassemia is a group of inherited anemias. Vietnam is a country with a high prevalence of thalassemia in the world: About 3% of the population carries the thalassemia gene, the prevalence is about 0.5-1% for the Kinh ethnic group, and a high increase of 10-25% in the Kinh population. some hill tribes. Early diagnosis and treatment of thalassemia reduces morbidity and mortality from thalassemia. Next, is BIMEDCHIP Non-tuberculous Mycobacteria Panel Kit for TB diagnosis. This kit provides results quickly, in as little as 6 hours, compared to traditional culture methods that can take weeks. Providing fast and accurate results helps medical staff to provide effective and timely treatment regimens, bringing benefits to patients. In particular, BIMEDCHIP Cardiovascular Drug PGx Testing Kit allows to detect whether a patient has changes in genes related to liver metabolism of Clopidogrel, Statin, Sinthrome drugs or not in a single test, thereby helping medical staff choose the right dose or drug for each patient, bringing the best effect for drug use. The successful implementation of the project is expected to contribute to improving the current limited production of medical equipment in Vietnam, meeting the increasing health care needs of the community, and at the same time. making an important contribution to the successful implementation of the Program on the development of a number of high-tech industries.

The content of strategic cooperation between the Central Institute of Hematology – Blood Transfusion and Roche Vietnam includes the following main activities: Organize specialized training programs and conferences to improve the capacity and experience of health workers in the care and treatment of hematological diseases; Support and connect the Central Institute of Hematology and Blood Transfusion to approach and participate in cooperation activities with agencies and organizations in Vietnam as well as internationally with the aim of learning and sharing treatment experiences from domestic and foreign experts and specialized centers; Organize activities aimed at patients and the community to propagate and raise awareness about diagnosis and treatment, focusing on hemophilia and non-Hodgkin lymphoma. The Central Institute of Hematology and Blood Transfusion in collaboration with Roche Vietnam organized a memorandum of understanding TS. BS. Bach Quoc Khanh, Director of the Central Institute of Hematology – Blood Transfusion, said: “We always support all the cooperation and support of prestigious organizations in the world for the development of Vietnamese health. , all for the goal of bringing better quality of treatment for patients who unfortunately suffer from blood clotting disorders and malignant blood diseases ”. Mr. Girish Mulye, General Director of Roche Pharma Vietnam emphasized: “Combining Roche’s global strengths and innovative solutions with expertise with the dedication and expertise from the medical team, we wishes to give more opportunities to those unlucky people suffering from this incurable disease. This is also part of the company’s long-term commitment to public health in reducing mortality caused by this group of diseases ”. Hemophila (also known as hemophilia) is an inherited bleeding disease caused by decreased or abnormal function of clotting factor VIII / IX. It is estimated that in Vietnam, there are more than 6,200 people with hemophilia, of which nearly 40% of the patients have not been diagnosed and treated. Non-Hodgkin’s lymphoma is another malignancy that tends to increase rapidly among the elderly in Vietnam, especially in men. In 2018, Vietnam had more than 3,500 new cases and more than 2,100 deaths, ranking 14th in terms of incidence rates among cancers. Like other hematological diseases, Hemophila and non-Hodgkin lymphoma cannot be completely cured, but if detected early and responded well to treatment, patients can still maintain their health and live almost life. normal. The Memorandum of Understanding between the Central Institute of Hematology – Blood Transfusion and Roche Vietnam is expected to be implemented within a year and will be in operation from April 2021. Through domestic and foreign cooperation, this strategic cooperation is expected to bring about many positive changes, helping to strengthen the capacity for hematological care and treatment.